ひとことで言うと
Prime Medicine was created to turn prime editing, the search-and-replace technique, into medicines. Its first therapy, for a rare immune disease, became the first prime-editing treatment given to patients, with results published showing the corrected cells took hold and restored the missing immune function.
Prime Medicine was founded in 2019 by David Liu, Andrew Anzalone and Keith Gottesdiener to develop prime editing therapeutics. PM359, correcting the NCF1 delGT mutation in p47phox-deficient chronic granulomatous disease, produced the first published first-in-human prime-editing results in the New England Journal of Medicine. The company has also pursued liver programmes including Wilson's disease.
Sources
- New England Journal of Medicine · 2025
Prime Editing for p47phox-Deficient Chronic Granulomatous Disease ↗
投資アドバイスではありません
このプロフィールは、公開情報をもとに作成した教育目的の情報です。いかなる有価証券の購入・売却・保有を推奨するものでも、企業の見通しに関する見解を示すものでもありません。バイオテクノロジーは投機性が高く、ほとんどの臨床プログラムは失敗に終わります。
免責事項の全文 →